920-106 Related Links

920-106 Dropmark  |   920-106 Wordpress  |   920-106 Dropmark-Text  |   920-106 Blogspot  |   920-106 RSS Feed  |   920-106 Box.net  |   920-106 zoho.com  |   920-106 publitas.com  |   920-106 Issu  |  
Pass4sure 920-106 cert prep. - Killexams

Real Exam Questions/Answers of 920-106

Killexams Updated 920-106

Complete examcollection is provided Here   |   View Vendors, Tracks Home

920-106 - NNCSS SYMPOSIUM CALL CENTER - BrainDump Information

Vendor Name : Nortel
Exam Code : 920-106
Questions and Answers : 90 Q & A
Updated On : March 19, 2019
PDF Download Mirror : 920-106 Braindumps
Get Full Version : Killexams 920-106 Full Version

killexams.com 920-106 NNCSS SYMPOSIUM CALL CENTER exam brain dumps with practice software.

We have our experts working continuously for the gathering of actual exam questions of 920-106. All the pass4sure questions and answers of 920-106 collected by our team are reviewed and up to date by way of our 920-106 licensed crew. We continue to be related to the candidates seemed inside the 920-106 exam to get their reviews approximately the 920-106 test, we acquire 920-106 exam recommendations and hints, their revel in about the techniques used inside the actual 920-106 exam, the errors they completed in the actual test after which improve our material thus. Once you go through our pass4sure questions and answers, you will sense assured approximately all of the topics of test and experience that your expertise has been significantly improved. These pass4sure questions and answers are not just exercise questions, these are real exam questions and answers which are enough to pass the 920-106 exam in the first attempt.

Nortel certifications are pretty required throughout IT businesses. HR managers decide on applicants who not simplest have an expertise of the subject, but having finished certification tests within the subject. All the Nortel certifications furnished on Pass4sure are ordinary global.

Are you looking for pass4sure actual exams questions and answers for the NNCSS SYMPOSIUM CALL CENTER exam? We are right here to offer you one most updated and great assets that is killexams.com. They have compiled a database of questions from actual exams for you to put together and pass 920-106 exam on the first attempt. All education materials on the killexams.com website are up to date and confirmed by means of certified professionals.

Why killexams.com is the Ultimate choice for certification instruction?

1. A quality product that Help You Prepare for Your Exam:

killexams.com is the closing training source for passing the Nortel 920-106 exam. We have carefully complied and assembled actual exam questions and answers, which are up to date with the same frequency as actual exam is updated, and reviewed by means of industry specialists. Our Nortel certified professionals from a couple of groups are talented and qualified / licensed people who've reviewed each question and answer and explanation section in order that will help you apprehend the idea and pass the Nortel exam. The pleasant manner to prepare 920-106 exam isn't reading a textual content e book, however taking exercise real questions and information the appropriate solutions. Practice questions assist prepare you for now not best the ideas, however additionally the approach wherein questions and answer options are presented in the course of the real exam.

2. User Friendly Mobile Device Access:

killexams provide extremely user friendly access to killexams.com products. The consciousness of the website is to offer accurate, up to date, and to the point cloth to help you have a look at and pass the 920-106 exam. You can fast get the actual questions and solution database. The website is cellular pleasant to permit look at everywhere, as long as you've got net connection. You can just load the PDF in mobile and study everywhere.

3. Access the Most Recent NNCSS SYMPOSIUM CALL CENTER Real Questions & Answers:

Our Exam databases are frequently up to date for the duration of the yr to include the modern actual questions and answers from the Nortel 920-106 exam. Having Accurate, proper and cutting-edge real exam questions, you'll pass your exam on the first strive!

4. Our Materials is Verified through killexams.com Industry Experts:

We are doing struggle to supplying you with correct NNCSS SYMPOSIUM CALL CENTER exam questions & answers, in conjunction with reasons. We make the price of your time and money, that is why each question and answer on killexams.com has been validated by Nortel certified experts. They are particularly certified and certified people, who've many years of expert enjoy related to the Nortel exams.

5. We Provide all killexams.com Exam Questions and Include Detailed Answers with Explanations:

killexams.com Huge Discount Coupons and Promo Codes are as underneath;
WC2017 : 60% Discount Coupon for all tests on internet site
PROF17 : 10% Discount Coupon for Orders greater than $69
DEAL17 : 15% Discount Coupon for Orders extra than $ninety nine
DECSPECIAL : 10% Special Discount Coupon for All Orders

Unlike many different exam prep websites, killexams.com gives not most effective updated actual Nortel 920-106 exam questions, but also specific answers, references and diagrams. This is essential to help the candidate now not best recognize an appropriate answer, but also details about the options that have been wrong.

920-106 dumps, 920-106 Discount Coupon, 920-106 Promo Code, 920-106 vce, Free 920-106 vce, Download Free 920-106 dumps, Free 920-106 brain dumps, pass4sure 920-106, 920-106 practice test, 920-106 practice exam, killexams.com 920-106, 920-106 real questions, 920-106 actual test, 920-106 PDF download, Pass4sure 920-106 Download, 920-106 help, 920-106 examcollection, Passleader 920-106, exam-labs 920-106, Justcertify 920-106, certqueen 920-106, 920-106 testking

View Full Exam »

Customer Reviews about 920-106

Testimonials Here   |   View Vendors, Tracks Home


Our customers are always happy to give their reviews about the exams. Most of them are our permanent users. They do not rely on others except our team and they get exam confidence by using our questions and answers and exam simulator.

preparing 920-106 exam is rely of some hours now.

Im ranked very immoderate amongst my elegance friends on the listing of top class college students however it besthappened when I registered in this killexams.com for a few exam assist. It become the high ranking studying programin this killexams.com that helped me in joining the immoderate ranks at the aspect of different splendid students of my magnificence. The assets on this killexams.com are commendable because of the reality they may be particular and extremely beneficial for preparationthru 920-106, 920-106 dumps and 920-106 books. I am satisfied to put in writing the ones terms of appreciation due to the truth this killexams.com merits it. Thank you.

Little effor, big output, brilliant Questions/solutions.

that is a gift from killexams.com for all of the candidates to get cutting-edge observe material for 920-106 exam. all themembers of killexams.com are doing a tremendous process and ensuring fulfillment of applicants in 920-106 checks. I handed the 920-106 exam just due to the fact I used killexams.com material.

updated and real exam bank of 920-106.

I gave the 920-106 practice questions great as quickly as in advance than I enrolled for turning into a member of the killexams.com software. I did no longer have achievement even after giving my enough of time to my research. I did no longer realize wherein i lacked in getting achievement. But after joining killexams.com i got my answer turned into lacking changed into 920-106 prep books. It positioned all the subjects inside the right guidelines. Getting geared up for 920-106 with 920-106 instance questions is honestly convincing. 920-106 Prep Books of different education that i had did assist me as they had been not enough capable for clearing the 920-106 questions. They have been tough in truth they did now not cover the complete syllabus of 920-106. However killexams.com designed books are really notable.

Try out these real 920-106 dumps.

Your consumer thoughts help experts were continuously available through stay chat to tackle the maximum trifling troubles. Their advices and clarifications have been vast. This is to light up that I found out how to pass my 920-106 Security exam via my first utilizing killexams.com Dumps direction. Exam Simulator of 920-106 by killexams.com is a superb too. I am amazingly pleased to have killexams.com 920-106 route, as this valuable material helped me obtain my targets. Much liked.

It was first experience but Great Experience!

I sought 920-106 help on the internet and discovered this killexams.com. It gave me numerous cool stuff to test from for my 920-106 check. Its needless to say that i was able to get via the test without issues.

920-106 exam prep got to be this easy.

To get success in 920-106 exam. people believe that a student must possess sharp brain. Although it is true but it is not entirely true since along with the student, the coach or the instructor must also be well qualified and educated. I feel blessed that I was acquainted with this killexams.com where I met such great educators who taught me how to clear my 920-106 test and got me through them with a breeze. I thank them with the bottom of my heart.

I had no time to study 920-106 books and training!

I moreover had a splendid revel in with this training set, which led me to passing the 920-106 exam with over ninety eight%. The questions are real and valid, and the exam simulator is a tremendous/guidance device, despite the fact that you are no longer planning on taking the exam and sincerely want to expand your horizons and enlarge your knowledge. i have given mine to a pal, who also works on this place but clearly received her CCNA. What I imply is its a splendid reading device for absolutely everyone. And if you plan to take the 920-106 exam, this is a stairway to achievement :)

Real 920-106 test questions! I was not expecting such shortcut.

Me and my roommate have been dwelling together for a long term and we have loads of disagreements and arguments concerning numerous topics however if there may be one issue that each humans agree on it is the truth that this killexams.com is the excellent one at the internet to use if you want to pass your 920-106 . Both people used it and feature beenvery happy with the very last consequences that we had been given. I used with the intention to carry out well in my 920-106 test and my marks were certainly brilliant. Thanks for the guidance.

i found the entirety had to bypass 920-106 exam here.

killexams.com Q&A is the most ideal way I have ever gone over to get ready and pass IT exams. I wish more individuals thought about it. Yet then, there would be more risks someone could shut it down. The thing is, it provides for the same thing what I have to know for an exam. Whats more I mean diverse IT exams, 920-106 with 88% marks. My associate utilized killexams.com Q&A for Many different certificates, all great and substantial. Completely solid, my individual top picks.

Observed maximum 920-106 Questions in Latest dumps that I prepared.

I have been so inclined my entire manner yet I recognize now that I had to get a pass in my 920-106 and this may make me popular likely and sure i am brief of radiance yet passing my tests and solved almost all questions in just75 mins with killexams.com dumps. Multiple awesome men cant convey a exchange to planets way however they could simply will assist you to realise whether or not youve got been the precept fellow who knew a way to try this and i need to be recognized in this international and make my own unique imprint.

View Practice Questions »

See more Nortel exam dumps

Direct Downloads Here   |   View Vendors, Latest Home

Real Exam Questions and Answers of exams

We offer a huge collection of Nortel exam questions and answers, study guides, practice exams, Exam Simulator.

922-090 | 920-432 | 920-254 | 922-101 | 922-080 | 920-470 | 920-138 | 920-157 | 920-533 | 920-271 | 920-352 | 920-548 | 920-110 | 920-338 | 920-330 | 922-109 | 920-504 | 922-097 | 920-221 | 920-336 | 920-320 | 920-804 | 920-344 | 920-172 | 920-258 | 920-806 | 922-089 | 920-530 | 920-132 | 920-544 | 920-173 | 920-324 | 920-255 | 920-452 | 920-130 | 920-482 | 922-072 | 920-345 | 922-093 | 920-270 | 920-505 | 920-105 | 920-556 | 920-323 | 920-325 | 920-128 | 920-453 | 922-102 | 920-335 | 920-451 |

View Complete Nortel Collection »

Latest Exams added

Recently Updated Here   |   View Vendors, Latest Home

Latest Real Exam Questions and Answers Added to Killexams.com

We keep our visitors and customers updated regarding the latest technology certifications by providing reliable and authentic exam preparation material. Our team remain busy in updating 920-106 exam training material as well as reviewing the real exam changes. They try best to provide each and every relevant information about the test for the candidate to get good marks and come out of test center happily.

156-727-77 | 1Z0-936 | 1Z0-980 | 1Z0-992 | 250-441 | 3312 | 3313 | 3314 | 3V00290A | 7497X | AZ-302 | C1000-031 | CAU301 | CCSP | DEA-41T1 | DEA-64T1 | HPE0-J55 | HPE6-A07 | JN0-1301 | PCAP-31-02 | 1Y0-340 | 1Z0-324 | 1Z0-344 | 1Z0-346 | 1Z0-813 | 1Z0-900 | 1Z0-935 | 1Z0-950 | 1Z0-967 | 1Z0-973 | 1Z0-987 | A2040-404 | A2040-918 | AZ-101 | AZ-102 | AZ-200 | AZ-300 | AZ-301 | FortiSandbox | HP2-H65 | HP2-H67 | HPE0-J57 | HPE6-A47 | JN0-662 | MB6-898 | ML0-320 | NS0-159 | NS0-181 | NS0-513 | PEGACPBA73V1 | 1Z0-628 | 1Z0-934 | 1Z0-974 | 1Z0-986 | 202-450 | 500-325 | 70-537 | 70-703 | 98-383 | 9A0-411 | AZ-100 | C2010-530 | C2210-422 | C5050-380 | C9550-413 | C9560-517 | CV0-002 | DES-1721 | MB2-719 | PT0-001 | CPA-REG | CPA-AUD | AACN-CMC | AAMA-CMA | ABEM-EMC | ACF-CCP | ACNP | ACSM-GEI | AEMT | AHIMA-CCS | ANCC-CVNC | ANCC-MSN | ANP-BC | APMLE | AXELOS-MSP | BCNS-CNS | BMAT | CCI | CCN | CCP | CDCA-ADEX | CDM | CFSW | CGRN | CNSC | COMLEX-USA | CPCE | CPM | CRNE | CVPM | DAT | DHORT | CBCP | DSST-HRM | DTR | ESPA-EST | FNS | FSMC | GPTS | IBCLC | IFSEA-CFM | LCAC | LCDC | MHAP | MSNCB | NAPLEX | NBCC-NCC | NBDE-I | NBDE-II | NCCT-ICS | NCCT-TSC | NCEES-FE | NCEES-PE | NCIDQ-CID | NCMA-CMA | NCPT | NE-BC | NNAAP-NA | NRA-FPM | NREMT-NRP | NREMT-PTE | NSCA-CPT | OCS | PACE | PANRE | PCCE | PCCN | PET | RDN | TEAS-N | VACC | WHNP | WPT-R | 156-215-80 | 1D0-621 | 1Y0-402 | 1Z0-545 | 1Z0-581 | 1Z0-853 | 250-430 | 2V0-761 | 700-551 | 700-901 | 7765X | A2040-910 | A2040-921 | C2010-825 | C2070-582 | C5050-384 | CDCS-001 | CFR-210 | NBSTSA-CST | E20-575 | HCE-5420 | HP2-H62 | HPE6-A42 | HQT-4210 | IAHCSMM-CRCST | LEED-GA | MB2-877 | MBLEX | NCIDQ | VCS-316 | 156-915-80 | 1Z0-414 | 1Z0-439 | 1Z0-447 | 1Z0-968 | 300-100 | 3V0-624 | 500-301 | 500-551 | 70-745 | 70-779 | 700-020 | 700-265 | 810-440 | 98-381 | 98-382 | 9A0-410 | CAS-003 | E20-585 | HCE-5710 | HPE2-K42 | HPE2-K43 | HPE2-K44 | HPE2-T34 | MB6-896 | VCS-256 | 1V0-701 | 1Z0-932 | 201-450 | 2VB-602 | 500-651 | 500-701 | 70-705 | 7391X | 7491X | BCB-Analyst | C2090-320 | C2150-609 | IIAP-CAP | CAT-340 | CCC | CPAT | CPFA | APA-CPP | CPT | CSWIP | Firefighter | FTCE | HPE0-J78 | HPE0-S52 | HPE2-E55 | HPE2-E69 | ITEC-Massage | JN0-210 | MB6-897 | N10-007 | PCNSE | VCS-274 | VCS-275 | VCS-413 |

View Recently Added Exams »

See more dumps

Direct Downloads Here   |   View Vendors, Latest Home

Real Exam Questions and Answers of exams

Here are some exams that you can explore by clicking the link below. There are thousands of exams that we provide to our candidates covering almost all the areas of certifications.

000-068 | C9030-634 | C2090-620 | CMQ-OE | C4090-453 | C4040-251 | CUR-051 | E20-526 | CTEL | 000-783 | HP0-266 | HP2-B68 | 1T6-510 | HP3-X05 | C9560-659 | 312-50v9 | ECSS | 1Z0-876 | OMG-OCUP-100 | NO0-002 | CISSP | HPE2-E67 | P2170-013 | LOT-980 | 9A0-389 | 9L0-415 | S90-05A | ANCC-MSN | HPE2-E69 | LOT-840 | AVA | RHIA | 000-963 | 304-200 | 000-170 | CRFA | 000-578 | A4040-332 | C2030-284 | SEC504 | A2150-006 | E05-001 | 70-462 | TB0-105 | 500-052 | 190-522 | 1Z0-517 | ST0-250 | HP2-K21 | JN0-420 |

View Practice Questions »

Top of the list Vendors

Certification Vendors Here   |   View Exams, Latest Home

Industry Leading Vendors

Top notch vendors that dominate the entire world market by their technology and experties. We try to cover almost all the technology vendors and their certification areas so that our customers and visitors obtain all the information about test at one place.

Healthcare | Trainers | Motorola | Cisco | Fortinet | CIPS | IISFA | NCEES | Vmware | Business-Objects | ICDL | ISACA | DMI | 3COM | See-Beyond | OMG | Prince2 | NIELIT | ARM | Brocade | PMI | RSA | SPSS | EMC | SUSE | PARCC | APTUSC | Apple | HP | SNIA | Fujitsu | ExtremeNetworks | GuidanceSoftware | Foundry | Counselor | XML-Master | Magento | Zend | Certification-Board | Cloudera | Financial | Network-General | PTCB | Admission-Tests | AFP | ACT | Tibco | Symantec | ISEB | ISM |

View Practice Questions »

Sample Real Exam Questions/Answers

Certification Vendors Here   |   View Exams, Latest Home

920-106 Demo and Sample

Note: Answers are below each question.
Samples are taken from full version.

Pass4sure 920-106 dumps | Killexams.com 920-106 real questions | [HOSTED-SITE]

Killexams.com 920-106 Dumps and Real Questions

100% Real Questions - Exam Pass Guarantee with High Marks - Just Memorize the Answers

920-106 exam Dumps Source : NNCSS SYMPOSIUM CALL CENTER

Test Code : 920-106
Vendor Name : Nortel
Q&A : 90 Real Questions

Nice to hear that actual test questions of 920-106 exam are available.
I have earned higher scores in 920-106 certification with the help of quite inexpensive products. I got 920-106 exam engine to get rid of hard standards of this certification. I had sold 920-106 exam braindump to have splendid grades within the certification. It end up pinnacle choice due to the fact the ones merchandise are designed in line with my brain-set. It helped me to get read in fifteen days and after this brief time I had scored specific with the help of these practical merchandise consequently im writing to mention manner to all of you in your top class services.

it's miles unbelieveable, but 920-106 present day dumps are availabe right here.
Today I am very happy because I have got a very high score in my 920-106 exam. I couldnt think I would be able to do it but this killexams.com made me think otherwise. The online educators are doing their job very well and I salute them for their dedication and devotion.

No waste of time on searhching internet! Found exact source of 920-106 Q&A.
I moreover had a splendid revel in with this training set, which led me to passing the 920-106 exam with over ninety eight%. The questions are real and valid, and the exam simulator is a tremendous/guidance device, despite the fact that you are no longer planning on taking the exam and sincerely want to expand your horizons and enlarge your knowledge. i have given mine to a pal, who also works on this place but clearly received her CCNA. What I imply is its a splendid reading device for absolutely everyone. And if you plan to take the 920-106 exam, this is a stairway to achievement :)

Take whole gain state-of-the-art 920-106 actual examination Q&A and get licensed.
Going thru killexams.com Q&A has come to be a addiction whilst exam 920-106 comes. And with test springing up in pretty a whole lot 6 days Q&A changed into getting extra critical. But with subjects I want a few reference manual to move occasionally in order that i would get better help. Manner to killexams.com their Q&A that made it all easy to get the subjectsinterior your head easily which would in any other case might be no longer viable. And its far all because of killexams.com products that I controlled to gain 980 in my exam. Thats the highest marks in my beauty.

simply try those modern-day dumps and achievement is yours.
Knowing thoroughly about my time constraint, commenced out trying to find an clean way out before the 920-106 exam. After a protracted searh, placed the question and answers via way of killexams.com which without a doubt made my day. Offering all probably questions with their quick and pointed solutions helped hold near subjects in a brief time and felt happy to secure real marks inside the exam. The materials also are clean to memorise. I am inspired and satiated with my results.

much less effort, fantastic expertise, assured success.
I was 2 weeks short of my 920-106 exam and my preparation was not all done as my 920-106 books got burnt in fire incident at my place. All I thought at that time was to quit the option of giving the paper as I didnt have any resource to prepare from. Then I opted for killexams.com and I still am in a state of shock that I cleared my 920-106 exam. With the free demo of killexams.com, I was able to grasp things easily.

Did you attempted this outstanding supply cutting-edge 920-106 dumps.
killexams.com works! I passed this exam last fall and at that time over 90% of the questions were absolutely valid. They are highly likely to still be valid as killexams.com cares to update their materials frequently. killexams.com is a great organization which has helped me more than once. I am a regular, so hoping for discount for my next bundle!

Is there 920-106 exam new sayllabus?
I just bought this 920-106 braindump, as soon as I heard that killexams.com has the updates. Its genuine, they have covered all new areas, and the exam appears very fresh. Given the current update, their turn round time and help is top notch.

actual 920-106 questions and accurate solutions! It justify the charge.
because of 920-106 certificates you purchased many possibilities for security specialists development on your career. I wanted to development my vocation in information protection and desired to grow to be certified as a 920-106. if so I decided to take help from killexams.com and commenced my 920-106 exam training through 920-106 exam cram. 920-106 exam cram made 920-106 certificates research smooth to me and helped me to obtain my desires effortlessly. Now im able to say without hesitation, without this internet site I in no way passed my 920-106 exam in first strive.

How much does it cost 920-106 qustions bank with real dumps
Yes, the questions and answers could be very useful and i suggest it to all people who wants to take those checks. Congrats on a process nicely idea out and completed. I cleared my 920-106 tests.


VoIP certification tracks - Nortel's support certifications | killexams.com Real Questions and Pass4sure dumps

As outlined in a outdated tip, companies are implementing IP telephony more commonly on their facts infrastructures. The accelerated deployment has created a need for certified IP telephony engineers to deliver proven, most beneficial-of-breed expertise.

The IP telephony certifications Nortel at present presents are divided into four classes: guide specialist, Design expert, support skilled, and Design skilled. This tip discusses the Nortel support music.

assist specialist

The guide professional certifications are intended to demonstrate an individual's means to put into effect, operate, and troubleshoot a Nortel Networks IP Telephony answer. The support expert certification reflects a candidate with three to six months of event that can deal with pursuits technical issues of a common Nortel IP Telephony answer.

NNCSS - VoIP Succession BCM 3.0

This certification checks the skill to put into effect, function, and troubleshoot the company Communications supervisor three.0. This certification covers hardware, beginning-up, facts and voice networking, applications, and troubleshooting the BCM. To flow the certification, two checks need to be successfully completed: know-how requisites and Protocols for IP Telephony options, and Succession BCM three.0. The technology necessities and Protocols for IP Telephony solutions exam is an outline of convergence technologies.

NNCSS - CallPilot Rls. 2.0

This certification exams the means to put in force, function, and troubleshoot the VoIP CallPilot 2.0. This certification covers hardware, administration, interoperability with Meridian 1 switches, and security of a single website CallPilot system. To flow the certification, two tests must be successfully achieved: Meridian Database and CallPilot 2.0.

NNCSS - Symposium name middle Server or Symposium name center Server installation and protection

These two certifications look at various the skill to implement, operate, and troubleshoot the Symposium name center Server. both certifications cover hardware, utility installing, administration, and protection of Symposium call core Server 4.2, Symposium web client 4.0, and Symposium categorical three.0. besides the fact that children, the Symposium call center Server certification also tests the architecture, customized configuration and integration of the server. To pass either of those certifications, one exam have to be efficiently achieved: Symposium call center or Symposium call core installation and maintenance, respectively.

NNCSS - Symposium call center TAPI/Agent or call center TAPI/Agent installing and preservation

These two certifications verify the ability to put in force, operate, and troubleshoot the Symposium name center TAPI/Agent. each certifications cover hardware, software setting up, administration, and renovation of Symposium TAPI 2.three and Symposium Agent 2.three. however, the Symposium call center TAPI/Agent certification also checks the structure, integration, and custom configuration of the TAPI/Agent. To move both of those certifications, one examination must be efficaciously completed: Symposium call middle TAPI/Agent or Symposium call core TAPI/Agent Inst/leading, respectively.

NNCSS - Symposium specific call core or Symposium express name middle installation and renovation

These certifications examine the ability to enforce, function, and troubleshoot the Symposium specific name middle. both certifications cowl hardware, utility installing, administration, and protection of Symposium express call center four.2. despite the fact, the Symposium categorical call center certification also checks the structure and integration of the name middle. To flow both of the certifications, one examination ought to be efficiently accomplished: Symposium categorical call center or Symposium categorical call center Inst and Maint respectively.

NNCSS - VoIP Multimedia communique Server (MCS) 5100 2.0

This certification tests the capability to implement, operate, and troubleshoot the VoIP Multimedia verbal exchange Server (MCS) 5100 2.0. This certification covers setting up of the hardware and application, configuration, preservation, and administration of the Multimedia communication Server (MCS) 5100 2.0. To move the certification, two assessments must be efficiently achieved: expertise standards and Protocols for IP Telephony solutions, and VoIP Multimedia verbal exchange Server (MCS) 5100 2.0. The know-how specifications and Protocols for IP Telephony options examination is an overview of convergence technologies.

NNCSS - VoIP Succession 1000/1000M Rls. 3.0 DB Administrator

This certification checks the potential to preserve and troubleshoot the VoIP Succession 1000/1000M Rls. three.0 DB Administrator. This certification covers the structure, configuration, upkeep, and administration of the Meridian 1, Succession one thousand Rls. 3.0, and Succession 1000M Rls. 3.0 the use of simple Alternate Route alternative (BARS) and network Alternate Route selection (NARS). To circulate the certification, two tests need to be successfully completed: expertise requisites and Protocols for IP Telephony solutions, and Succession a thousand/1000M Rls. 3.0 DB Administrator.

NNCSS - VoIP Succession one thousand/1000M Rls. three.0 setting up and upkeep

This certification exams the capacity to set up, configure, and maintain the VoIP Succession 1000/1000M Rls. 3.0. This certification covers the setting up, structure, configuration, preservation, and administration of the Meridian 1, Succession one thousand Rls. 3.0, and Succession 1000M Rls. three.0, cyber web Telephones i2xxx, and Optivity Telephony manager (OTM) 2.1. To circulate the certification, three tests must be efficaciously achieved: know-how specifications and Protocols for IP Telephony solutions, and Succession 1000/1000M Rls. 3.0 for Technicians, and Succession 1000/1000M Rls. three.0.

support professional

The aid expert certifications build on the specialist's expertise by demonstrating their ability to put in force, operate, and troubleshoot an advanced Nortel Networks IP Telephony solution. The help professional certifications reflect a candidate with six to twelve months of fingers-on journey with the means to lead or aid intermediate-level personnel to preserve complex Nortel IP Telephony solutions.

NNCSE - CallPilot 2.0 Unified Messaging options

This certification assessments the ability to enforce, operate, troubleshoot and optimize the VoIP CallPilot Unified Messaging solution 2.0. This certification covers the installing, administration, interoperability, security, improve techniques and feature usage for a multi web site CallPilot system. To pass the certification, the candidate need to first gain their NNCSS - CallPilot Rls. 2.0. consequently, the CallPilot 2.0 Unified Messaging solutions have to be efficaciously completed to acquire this certification.

NNCSE - Contact middle

This certification checks the potential to put into effect, operate, troubleshoot and optimize the Contact center products. This certification covers the candidate's capabilities on the Symposium call middle Server (SCCS)/Symposium express call middle/Symposium net customer, Symposium TAPI service provider (TAPI SP), Symposium Agent, and the Symposium net center Portal. To circulate the certification, the candidate ought to first acquire their NNCSS - Symposium name center Server and the NNCSS - Symposium call center TAPI/Agent certification. in consequence, the Contact middle examination have to be correctly accomplished to reap this certification.

NNCSE - IP Convergence Succession 1000/1000M Rls. 3.0

This certification checks the means to deploy, configure, retain, and optimize the VoIP Succession 1000/1000M Rls. 3.0. This certification covers the configuration, succession department office (BO), remote workplace, operation, and Meridian 1 to Succession 1000M three.0 migration procedures for the Succession a thousand/1000M Rls. 3.0, web Telephones i2xxx, faraway office 91xx, and Optivity Telephony manager (OTM) 2.1. To pass the certification, the candidate have to first obtain their NNCSS - VoIP Succession CSE 1000 Rls. 2.0 or the VoIP Succession 1000/1000M Rls. 3.0 installing & maintenance certification. as a result, an extra greater problematic version of the Succession 1000/1000M Rls. three.0 examination should be efficaciously achieved to achieve this certification.

within the IT trade, certifications are a method to validate an individual's advantage within a exact area. The above Nortel IP Telephony certifications are probably the most equipment that may display the capabilities of an IP Telephony assist professional. These certifications couldn't substitute years of industry event, however they do deliver the foundation to support and manipulate Nortel Voice over IP solutions.

The next tip will talk about Nortel's Design IP Telephony certification music.

Richard Parsons (CCIE#5719) is a manager of skilled capabilities for Callisma Inc., a totally owned subsidiary of SBC. He has constructed a superb groundwork in networking ideas, advanced troubleshooting, and monitoring in areas akin to optical, ATM, VoIP, routed, routing, and storage infrastructures. rich resides in Atlanta GA, and is a graduate of Clemson institution. His heritage includes senior and predominant consulting positions at international network features, Lucent, and Callisma.

Bel Fuse (BELFB) this fall 2018 revenue conference call Transcript | killexams.com Real Questions and Pass4sure dumps

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

picture source: The Motley fool.

Bel Fuse (NASDAQ:BELFB)this autumn 2018 earnings convention CallFeb. 21, 2019 11:00 a.m. ET

  • organized Remarks
  • Questions and solutions
  • name participants
  • organized Remarks:


    first rate day, and welcome to the Bel Fuse Inc. fourth quarter and full-year 2018 results conference name. modern day convention is being recorded. at present, i want to show the convention over to Mr.

    Dan Bernstein, president and chief executive officer. Please go ahead, sir.

    Dan Bernstein -- President and Chief govt Officer

    thank you, Allison. becoming a member of me on the name nowadays is Craig Brosious, our vice president of Finance; and Lynn Hutkin, our director of fiscal reporting. earlier than we start the call, i might like to ask Lynn to move over the secure harbor remark. Lynn?

    Lynn Hutkin -- Director of fiscal Reporting

    thank you, Dan. decent morning, everybody. before we start, i might like to read here secure harbor statement. except for historic suggestions contained on this call, the concerns discussed on this name corresponding to statements related to expected increase from the business's distribution channel, the results of the ERP system implementation and different high-quality business and increase traits are forward-searching statements as described below the inner most Securities Litigation Reform Act of 1995 that involves dangers and uncertainties.

    exact effects could fluctuate materially from those projections. among the factors that might trigger genuine consequences to vary materially from such statements are: the market considerations facing our purchasers; the continuing viability of sectors that count on our products; the outcomes of company and economic conditions; difficulties associated with integrating currently obtained agencies; means and supply constraints or difficulties; product building, commercialization or technological difficulties; the regulatory trade ambiance; dangers associated with foreign currency; uncertainties associated with prison proceedings; the market's acceptance of the business's new items and competitive responses to these new products; the influence of alterations to U.S. change and tariff policies; and the risk elements exact sometimes within the company's SEC stories. In easy of the hazards and uncertainties, there may also be no assurance that any forward-looking statement will, in fact, show to be proper.

    We undertake no obligation to update or revise any ahead-looking statements. We may additionally also talk about non-GAAP effects throughout this call and reconciliations of our GAAP consequences to non-GAAP effects were protected in our liberate. And simply earlier than turning the name back to Dan, I simply desired to supply each person a heads up that our EBITDA reconciliation table in our usual release became fallacious. there were errors in that desk and a brand new release is popping out.

    So please dismiss that preliminary desk. So it truly is the third table, which is on web page 7 of the liberate.

    Dan Bernstein -- President and Chief govt Officer

    thanks, Lynn. earlier than going throughout the financials, i want to provide a short update on how the companies did from an operational standpoint this quarter and what we see going ahead. usual, we're very completely satisfied that we closed the 12 months with a different strong quarter, bringing our 2018 sales to $548 million, our larger revenue year for the reason that 2015. extra importantly, our net income for the year of $21 million become the highest in over a decade.

    revenue all the way through the fourth quarter were $142.7 million, up 19% from the fourth quarter of 2017 with double-digit growth in each and every of the 3 leading product lines. Our backlog of orders remained mighty at $171.2 million at December 31, 2018, a rise of 17% from a 12 months in the past. The enhance in backlog is also considered across every of our main product companies, which is a good barometer for different future increase. and searching via at the full 12 months.

    Our Magnetic solutions neighborhood closed the 12 months with $24.4 million enhance in sales over 2017 stages led by high demand for our built-in connector modules that are used in next-technology switching functions. revenue of our signal Transformer items have been additionally potent right through 2018 as new courses with clinical and industrial purposes moved into full production. we now have also increased the presence of our magnetic items via our distribution channels, which add to the 12 months-over-12 months sales growth. The backlog of orders from magnetic items grew by way of $9.7 million or 28% enhance for the reason that the 2017 yr-end.

    Our Connectivity solutions neighborhood had yr-over-year revenue increase of $sixteen.four million. Our Cinch enterprise expanded profits via $8.2 million compared to 2017 led via mighty demand for optical and copper products utilized in encryption, communication and threat detection radar applications. Our Stewart passive connectors additionally saw boost in income of $8.2 million from 2017 as better financial conditions in the building business led to high demand for our premise wiring customs throughout the year. The Cinch and Stewart enterprise also benefit from wonderful increase in earnings through our distribution channel in 2018.

    average, the backlog of orders for our Connectivity products grew by using $7.8 million, or 16%, in view that 2017 12 months-conclusion stages. Our power options and insurance policy community had a turnaround yr as revenue boom of $15.8 million from 2017 led this community to its first 12 months of sales increase when you consider that 2015. with the exception of the consequences of our NPS divestiture, sales for this group were up $21 million or 14% from closing 12 months, pushed by way of continued demand for our power supplies in diversity of information core functions. sales of our DC to DC and circuit insurance policy products also grew in 2018, offset by using a decline favorite for our custom modules.

    The backlog of our orders for our vigour solutions and insurance policy community is up $7.1 million or eleven% from 2017 yr-conclusion levels. From a profitability standpoint, overseas trade good points and a good adjustment draw the transition tax out to mitigate the larger labor and fabric charges that impacted our bottom line this yr. We proceed to hang pricing company as we work through our higher cost stock on end. concerning the tariffs that had been implemented in 2018, we estimate that about 10% of our consolidated annual revenues are at the moment impacted.

    At this element, the bulk of these charges have been handed along to our customers in the form of invoice can charge. We proceed to monitor the situation carefully as we method the tentative March 1 time limit for the U.S. accomplishing a pretty good cope with China in all event extra increases on existing tariffs. typical, we stay cautiously confident with the continued income boom and profitabilities as we enter 2019.

    And with that, i would flip it over to Craig to run in the course of the fiscal replace.

    Craig Brosious -- vice president of Finance

    Thanks, Dan. To supply a quick recap on income. revenue during the fourth quarter were $142.7 million. through geographic segment, North america earnings have been $70.3 million, Asia income were $49.1 million and Europe have been $23.3 million.

    with the aid of product neighborhood, Connectivity solutions income had been $46.four million, Magnetic solutions income were $forty eight.6 million and vigour options and insurance plan revenue were $47.7 million. Gross profit margin expanded to 21.3% in the fourth quarter of 2018 as in comparison with 18.5% within the fourth quarter of 2017 as incremental earnings in 2018 ended in more suitable fastened can charge absorption offsetting larger labor expenses all over the yr. moreover, our gross earnings margin all through the fourth quarter of 2017 have been impacted through inventory-related costs totaling $2 million in connection with keeping our stock on the lower can charge or net realizable cost. Our selling, commonplace and administrative expenses were $22.2 million or 15.6% of income as in comparison with $21.1 million or 17.6% of income in the fourth quarter of 2017.

    while the increase in SG&A costs all the way through the 2018 length $900,000 pertains to a decline in market price of our COLI policies, which changed into in accordance with the normal inventory market recreation during the fourth quarter of 2018. we now have already began to peer this reverse in 2019. different offsetting components that affected that the variance in the fourth-quarter durations had been better legal and expert charges of $800,000 offset by using a lessen in unhealthy debt price of $500,000 and a discount in depreciation and amortization of $four hundred,000. On a go-ahead groundwork, we might predict SG&A to run between $20 million and $21 million per quarter within the close time period, barring any huge fluctuations in foreign currency echange.

    because of these factors, we generated earnings from operations of $8 million in the fourth quarter of 2018 as in comparison to $1 million within the fourth quarter of 2017. pastime expense changed into -- i'm sorry, $1.4 million in the fourth quarter of 2018, down $900,000 from the identical duration closing yr. in case you keep in mind, we refinanced our credit agreement in the fourth quarter of 2017, which ended in an acceleration of deferred financing cost amortization of $1 million during the remaining year's fourth quarter. Our provision for profits taxes became $2.four million for the fourth quarter of 2018 compared to $19.2 million all through final year's fourth quarter.

    the supply for revenue taxes right through the fourth quarter of 2018 was unfavorably impacted via taxes on international salary, the GILTI tax, partially offset by a decrease within the U.S. tax price from 35% to 21% in 2018. the availability for revenue taxes in 2017 period included an $18 million impact from the U.S. Tax Cuts and Jobs Act, which become enacted on December 22, 2017.

    profits per share for category a common shares was $0.31 per share in the fourth quarter of 2018 as compared with a loss of $1.sixty six per share in the fourth quarter of 2017. earnings per share for class B general shares was $0.33 per share within the fourth quarter of 2018 as compared with the lack of $1.seventy four per share in the fourth quarter of 2017. On a non-GAAP groundwork, which excludes certain peculiar and different nonrecurring items, EPS for category A shares become $0.37 per share in the fourth quarter of 2018 as compared with the loss of $0.09 per share in the fourth quarter of 2017. On a non-GAAP groundwork, EPS for class B shares turned into $0.39 per share in the fourth quarter of 2018 as in comparison with a lack of $0.10 per share within the fourth quarter of 2017.

    And now i would like to go through some stability sheet and cash circulation gadgets. Our money and cash equivalents balance at December 31, 2018, changed into $fifty three.9 million, a lessen of $15.4 million from December 31, 2017. right through 2018, we made payments of $9 million towards our amazing debt steadiness. We also used cash for capital charges of $11.6 million, dividend funds of $3.3 million and hobby funds of $four.8 million.

    money owed receivable were $ninety one.9 million at December 31, 2018 as compared with $78.8 million at December 31, 2017. Days income striking have been 59 days at December 31, 2018, compared to 60 days at December 31, 2017. The boost in debts receivable stability changed into generally because of the bigger revenue volume within the fourth quarter of 2018 as compared to the fourth quarter of 2017. Inventories were $120.1 million at December 31, 2018, up $12.three million from December 31, 2017.

    In January of 2018, we adopted the new income cognizance regular, which hastens the timing during which we earnings become identified and the corresponding liberate of comprehensive items from our stock balance concerning items held at customer control hubs. except for the results of this adoption, our stock stability would have elevated by $23.4 million from December 31, 2017, essentially uncooked materials and work-in-growth in keeping with the enhance well-known for our products in 2018. accounts payable had been $fifty six.2 million at December 31, 2018, up $8.2 million from its degree at December 31, 2017 because of the raise in raw material purchases. Bel's total fantastic debt turned into reduced with the aid of $744,000 during the fourth quarter, bringing the balance down to $116 million as of December 31, 2018, aside from deferred financing cost.

    ebook cost per share, which is calculated as stockholders' equity divided by way of our combined A and B classes of normal inventory impressive, become $14.39 per share at December 31, 2018 as in comparison to $13.13 per share at December 31, 2017. And now i want to show the name returned to Dan and open the call for questions.

    Dan Bernstein -- President and Chief government Officer

    yes. do we open up the demand questions, please, Allison? 

    Questions and answers:


    actually, sir. [Operator instructions] we are able to now take our first question from Sean Hannan from Needham & enterprise. Please go ahead, sir.

    Sean Hannan -- Needham and enterprise -- Analyst

    yes. Thanks. respectable morning, everyone. Dan, i used to be looking to see if I might ask you might provide us with a little bit of detail across the phase.

    i do know you offered some on your prepared feedback. can you in all probability get into a bit bit extra specificity when it comes to how had been you feeling with each of these section nowadays and the actions we ramp right here within the first quarter and in '19. and perhaps how that may additionally have trade or could be different versus what you were expecting probably just a couple of months in the past? Any perception there could be very effective. Thanks.

    Dan Bernstein -- President and Chief govt Officer

    adequate. Of path, all of our product businesses and all of the subdivisions inside the product corporations, a majority, i would say, 80% of all were very robust. we now have one community, is the Modular group and the DC to DC neighborhood out of Italy which have some tremendous clients that they misplaced, but that hasn't been the rest to do with the market conditions simply on account of the situation with these clients. So ordinary everything has been, as you be aware of, extraordinarily fine.

    Going into this quarter and subsequent quarter, January become a very -- we saw a strong January, and once again, we suppose we do not see any alterations within the first quarter. The handiest concerns that we do have is there are some IC businesses that are seeing some softening in the market and we do hear some rumblings that there may be too a lot inventory in the pipeline. but to this point it has not affected our revenue or backlog. So again, it's why I consider we're a bit wonderful for the first quarter and for instance, I suppose close out after that.

    Sean Hannan -- Needham and company -- Analyst

    adequate. fair ample. Now as we seem into the power neighborhood, it is definitely always a topic on each and every name. there's a whole lot that you've done when it comes to correcting the nice concerns from one of the vital acquisitions you've got taken on, there's a great deal you could have been doing to step-up executions, plenty that you have executed in incrementally successful new designs and into new programs some of which has been getting some momentum.

    and that i suppose you said that a bit bit earlier today. What extra may still we expect within the trajectory of these organizations? Is there the rest within the history that's incrementally being labored down or is obtainable a bogey that might speed up the boom trajectory that you're now atmosphere into today? Or how should still we consider about how this continue to enhance as a product section for you? Thanks.

    Dan Bernstein -- President and Chief govt Officer

    good enough. So the vigor community, again, as we brought up over the ultimate two or three years, we trust very strongly that has the best boom expertise for Bel from a accurate-line standpoint. On the power, we did have is after we acquired the company previous administration truly failed to center of attention on pleasant and customer service. And it took us a very long time to exchange that; a, first change our manufacturing unit then exchange the client opinion, and over the last 18 months, we now have all our purchasers are back and believe Bel to be a power corporation.

    I feel two issues that we now have achieved that we now have changed these days. One became, I consider, as we have been so desperate for earnings, we took a shotgun approach and really put all restrain on our R&D community without getting the type of effects that we would like. So what we've performed is, truly long past from much greater chosen method of what consumers you need to deal with, how they fit into us and should they be long-time period shoppers? With that said, we are streamlining our R&D community because we will not have to go with the southbound method, we comprehend what precisely engineers we deserve to guide these products as we circulate ahead. the key difficulty now could be that we do have two or key key customers that may go anywhere from $eight million to $12 million, $13 million.

    And once we're talking about statistics middle-category of customer, we do have big customer classification of valued clientele. again, those fluctuate very big from a earnings standpoint. once more, however, we do think that we've located ourselves much more within the market, and currently I feel we now have 90 NDA signed on high-effectivity vehicles and we're starting to see that enterprise go from $three million to $5 million. So we're hoping that would double once more, offers us a lot more diversification, and we are working with different information center classification of customers.

    So we get that greater assorted. So again, we are still taking pictures. Our goal has all the time been to get vigour to that consistent 10% increase over a two to three-12 months period.

    Sean Hannan -- Needham and enterprise -- Analyst

    good enough. that's beneficial. and then closing query right here. just to see if i will be able to get some standpoint round a customer of yours without delay or ultimately.

    Huawei, I remember you might be now not necessarily even a 5% consumer, but are you able to focus on how do they play into your enterprise traditionally? And is there the rest that we should still consider of thinking about that relationship or income technology and maybe by some means tied to them on a go-forward groundwork? Thanks.

    Dan Bernstein -- President and Chief executive Officer

    neatly, I suppose, again, being a chinese language business, I think they are inclined to go along with chinese providers in China. i know, for instance, they offered their vigor provide neighborhood to Emerson about six years ago, and now former Huawei individuals have their own vigor give company. So we know it's a troublesome nut to crack. We do some ICM enterprise, however no longer vast in any respect.

    And for us, it's going to be a strong advantage as a result of we think people like Nortel, Cisco should still prefer up the company that they're losing. So i do know there are certain nations, Czech Republic, even Canada and the U.S. how they view Huawei going ahead. And that they cannot buy equipment from Huawei for 5G, they will doubtless go with -- I failed to mean Nortel, I ask for forgiveness, Nokia, that Nokia and Cisco will likely choose up that slack and might be Alcatel, and these multinational non-chinese language purchasers we do big quantity of business with them.

    So we're hoping that our business should still increase as more and more 5G is delivered.

    Sean Hannan -- Needham and company -- Analyst

    Very first rate. Thanks so tons, folks.


    [Operator instructions] And we will now take a question from Hendi Susanto from G. analysis. Please go forward.

    Hendi Susanto -- G. analysis -- Analyst

    first rate morning. Dan, you commute to China a great deal. How do you signify your China market now? How different is it in comparison to a typical 12 months?

    Dan Bernstein -- President and Chief executive Officer

    We at all times -- for us -- all over the realm, I imply, Europe and China there may be so a lot uncertainty and how they trust in Donald Trump and the job he's doing. there's giant amount of anxiousness. For us again, for the China market, or not it's always been very complex to ruin into that market as a result of the pricing parameters that you've got promoting to, again, a chinese language consumer. although, a good component can be 35% of our sales go to China, but it surely goes throughout the CEM like the Flextronics or Hon Hai, Foxconn, and those are non-chinese groups.

    youngsters, we do -- we are starting to see more americans look at China in a distinct easy. We recognize the ODMs in Taiwan, they have majority of their production in China. They at the moment are moving a few of that creation lower back into Taiwan. We see other multinationals relocating products round to get across the tariffs.

    So when you've got production in Malaysia, use that for all items coming to the States after which you use your China production to go into Europe and the a long way East market. but once again, no one likes uncertainty and that without query with the tariffs there's giant amount of uncertainties and that's not first rate for anyone.

    Hendi Susanto -- G. research -- Analyst

    got it. after which Dan, given solid income growth and your backlog boom in 2018 and existing ERP implementation, how a good deal development in gross margin and working margin we should expect in 2019?

    Dan Bernstein -- President and Chief executive Officer

    i will depart that to my accounting neighborhood here.

    Craig Brosious -- vice president of Finance

    yes. I consider assuming the within your budget sales increase that we're expecting, moderate income increase, I believe we have some leverage means to movement the gross margin up to maybe a point, aspect and a half. once more, lots of our construction costs are primarily based in the -- in China and counting on which approach the trade agreements go, it may have an effect on the change fees that we should deal with on the can charge of that -- on the labor costs, exceptionally. So barring any massive moves in these change charges, we've opportunities to extend margins a bit bit.

    Hendi Susanto -- G. research -- Analyst

    after which a further question on charge. So I think Bel Fuse is coping with enhance in labor charge, and that i suppose that has been there for a long time after which you were mitigating or taking movements or improved your labor charge. after we move through like 2019, when can we examine on an apple-to-apple 12 months-over-12 months assessment in regards to the labor can charge? And like how -- and then be sure you be in a position to quantify how an awful lot labor charge become?

    Craig Brosious -- vice chairman of Finance

    I believe we -- to get to an apples-to-apples comparison, we are able to likely should get within the third quarter of this year because we had charge raises going into impact within the first and second quarters of 2018. So I feel as soon as we get to the third quarter, we get some low cost comparatives.

    Lynn Hutkin -- Director of fiscal Reporting

    The most effective aspect to add there's, in 2019, we're also experiencing elevated labor charge in Mexico so that you can affect the 2019 length, however changed into not there right through the 2018 period. So we have that as smartly.

    Hendi Susanto -- G. analysis -- Analyst

    adequate. and then the majority of the tariff cost has been passed to clients. can you quantify how a great deal has been handed and what's next?

    Dan Bernstein -- President and Chief executive Officer

    I consider it's been about $7.eight million, in that latitude.

    Lynn Hutkin -- Director of fiscal Reporting

    In 2018, it become about $2.four million, in total for 2018, in order that become a partial -- that was a partial 12 months.

    Craig Brosious -- vice chairman of Finance

    So like Dan had mentioned previously, most of our sales as a minimum coming out of China don't become without delay into the U.S. So we're not enormously impacted through the tariffs. So we have been capable of -- basically $2.5 million or in order that we needed to add.

    Hendi Susanto -- G. analysis -- Analyst

    good enough. acquired it. thanks.


    [Operator instructions] It appears there aren't any additional questions. Mr. Bernstein, i would like to show the call back to you for any additional or closing remarks.

    Dan Bernstein -- President and Chief govt Officer

    thank you for joining us nowadays, and we seem to talking to you sooner or later. thanks to your time.


    [Operator signoff]

    length: 29 minutes

    call members:

    Dan Bernstein -- President and Chief government Officer

    Lynn Hutkin -- Director of monetary Reporting

    Craig Brosious -- vp of Finance

    Sean Hannan -- Needham and enterprise -- Analyst

    Hendi Susanto -- G. research -- Analyst

    greater BELFB analysis

    this article is a transcript of this convention call produced for The Motley fool. while we try for our foolish premier, there could be mistakes, omissions, or inaccuracies during this transcript. as with all our articles, The Motley fool does not assume any responsibility for your use of this content material, and we strongly encourage you to do your personal analysis, together with listening to the call yourself and analyzing the business's SEC filings. Please see our phrases and conditions for additional details, together with our mandatory Capitalized Disclaimers of liability.

    10 shares we like enhanced than Bel FuseWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to hear. in spite of everything, the e-newsletter they've run for over a decade, Motley fool stock marketing consultant, has quadrupled the market.*

    David and Tom simply printed what they agree with are the 10 finest stocks for investors to buy right now... and Bel Fuse wasn't one in all them! it's appropriate -- they think these 10 stocks are even more advantageous buys.

    See the ten stocks

    *stock marketing consultant returns as of January 31, 2019

    Motley fool Transcribing has no place in any of the shares mentioned. The Motley idiot has no position in any of the shares mentioned. The Motley fool has a disclosure policy.

    Bel Fuse Inc. (BELFB) CEO Daniel Bernstein on this autumn 2018 consequences - income name Transcript | killexams.com Real Questions and Pass4sure dumps

    No result discovered, are trying new keyword!Bel Fuse Inc. (NASDAQ:BELFB) this fall 2018 results profits convention call February 21 ... demand for our vigor substances in diversity of data middle purposes. earnings of our DC to DC and circuit ...

    While it is hard errand to pick solid certification questions/answers assets regarding review, reputation and validity since individuals get sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets as for exam dumps update and validity. The greater part of other's sham report objection customers come to us for the brain dumps and pass their exams cheerfully and effortlessly. We never bargain on our review, reputation and quality because killexams review, killexams reputation and killexams customer certainty is imperative to us. Extraordinarily we deal with killexams.com review, killexams.com reputation, killexams.com sham report grievance, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. On the off chance that you see any false report posted by our rivals with the name killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com protestation or something like this, simply remember there are constantly terrible individuals harming reputation of good administrations because of their advantages. There are a great many fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams rehearse questions, killexams exam simulator. Visit Killexams.com, our example questions and test brain dumps, our exam simulator and you will realize that killexams.com is the best brain dumps site.


    000-137 free pdf | M9560-760 braindumps | TK0-201 brain dumps | OG0-9AB questions and answers | HP2-E15 real questions | 1Z0-567 Practice test | 000-318 pdf download | 00M-230 cheat sheets | CISM mock exam | A2040-956 free pdf download | 650-575 Practice Test | 1Z0-547 bootcamp | M2010-719 examcollection | 650-316 practice test | 270-411 free pdf | 77-883 practice test | 1Z0-325 sample test | 1Z0-599 braindumps | 000-913 exam prep | 000-005 practice questions |

    Ensure your success with this 920-106 question bank
    Is it accurate to say that you are searching for Nortel 920-106 Dumps of real questions for the NNCSS SYMPOSIUM CALL CENTER Exam prep? We give as of late refreshed and incredible 920-106 Dumps. Detail is at http://killexams.com/pass4sure/exam-detail/920-106. We have gathered a database of 920-106 Dumps from real exams on the off chance that you need to can enable you to assemble and pass 920-106 exam on the first attempt. Simply set up together our Q&A and unwind. You will pass the exam.

    killexams.com high value 920-106 exam simulator will be facilitating for our customers for the test steering. All vital functions, practice questions and definitions are highlighted in 920-106 brain dumps pdf. Gathering the records in one region will be a real time saver and makes you confident for the NNCSS SYMPOSIUM CALL CENTER exam within a brief time span. The 920-106 exam provides key points. The killexams.com with pass4sure dumps permits to memorize the essential questions or concepts of the 920-106 exam At killexams.com, we offer absolutely verified Nortel 920-106 practice questions that are the satisfactory for Passing 920-106 exam, and to induce certified with the assistance of 920-106 braindumps. It is a good option to accelerate your career as a specialist within the Nortel Technology. we are pleased with our quality of supporting humans pass the 920-106 exam of their first attempt. Our success fees at intervals the past 2 years were sure enough gorgeous, because of our happy shoppers currently ready to boost their career at the quick lane. killexams.com is the primary preference among IT specialists, above all those are trying to climb up the hierarchy of qualifications faster in their respective organization. Nortel is the enterprise leader in info generation, and obtaining certified will be assured to succeed with IT careers. we have an approach to assist you with our excessive best Nortel 920-106 brain dumps.

    killexams.com helps millions of candidates pass the exams and get their certifications. We have thousands of successful reviews. Our dumps are reliable, affordable, updated and of really best quality to overcome the difficulties of any IT certifications. killexams.com exam dumps are latest updated in highly outclass manner on regular basis and material is released periodically. Latest killexams.com dumps are available in testing centers with whom we are maintaining our relationship to get latest material.

    The killexams.com exam questions for 920-106 NNCSS SYMPOSIUM CALL CENTER exam is mainly based on two accessible formats, PDF and Practice questions. PDF file carries all the exam questions, answers which makes your preparation easier. While the Practice questions are the complimentary feature in the exam product. Which helps to self-assess your progress. The evaluation tool also questions your weak areas, where you need to put more efforts so that you can improve all your concerns.

    killexams.com recommend you to must try its free demo, you will notice the intuitive UI and also you will find it very easy to customize the preparation mode. But make sure that, the real 920-106 product has more features than the trial version. If, you are contented with its demo then you can purchase the actual 920-106 exam product. Avail 3 months Free updates upon purchase of 920-106 NNCSS SYMPOSIUM CALL CENTER Exam questions. killexams.com offers you three months free update upon acquisition of 920-106 NNCSS SYMPOSIUM CALL CENTER exam questions. Our expert team is always available at back end who updates the content as and when required.

    killexams.com Huge Discount Coupons and Promo Codes are as under;
    WC2017 : 60% Discount Coupon for all exams on website
    PROF17 : 10% Discount Coupon for Orders greater than $69
    DEAL17 : 15% Discount Coupon for Orders greater than $99
    DECSPECIAL : 10% Special Discount Coupon for All Orders


    Killexams LOT-803 Practice test | Killexams C9010-262 questions answers | Killexams 9A0-381 sample test | Killexams 000-918 real questions | Killexams P2170-035 exam prep | Killexams MSC-321 study guide | Killexams C2090-603 exam prep | Killexams 1Z0-932 cram | Killexams 310-875 practice questions | Killexams CWNA-107 questions and answers | Killexams 1Z0-439 practice exam | Killexams 000-651 pdf download | Killexams NCPT real questions | Killexams 000-451 practice test | Killexams MSC-331 questions and answers | Killexams ST0-086 examcollection | Killexams 1Z0-100 real questions | Killexams HP2-H65 practice test | Killexams 70-565-VB bootcamp | Killexams 000-N19 test questions |


    View Complete list of Killexams.com Brain dumps

    Killexams HP2-E46 free pdf | Killexams SK0-004 real questions | Killexams HP0-092 practice test | Killexams 00M-194 pdf download | Killexams 000-208 practice questions | Killexams APA-CPP study guide | Killexams 050-644 test prep | Killexams HP2-E15 dumps questions | Killexams MB2-527 Practice Test | Killexams HP2-B121 examcollection | Killexams P2170-036 questions and answers | Killexams 3I0-012 test prep | Killexams C2090-625 free pdf | Killexams 700-270 practice questions | Killexams MOS-A2K cheat sheets | Killexams 310-065 exam questions | Killexams 000-976 cram | Killexams PCCE test prep | Killexams LOT-915 practice exam | Killexams 050-CSEDLPS test questions |


    Pass 4 sure 920-106 dumps | Killexams.com 920-106 real questions | [HOSTED-SITE]

    Strongbridge Biopharma plc (SBBP) Q4 2018 Earnings Conference Call Transcript | killexams.com real questions and Pass4sure dumps

    Logo of jester cap with thought bubble.

    Image source: The Motley Fool.

    Strongbridge Biopharma plc  (NASDAQ:SBBP)Q4 2018 Earnings Conference CallFeb. 26, 2019, 8:30 a.m. ET

  • Prepared Remarks
  • Questions and Answers
  • Call Participants
  • Prepared Remarks:


    Good morning, ladies and gentlemen, and welcome to the Strongbridge Biopharma Corporate Update and Fourth Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this call will be recorded.

    I would now like to introduce your host for today's conference, Ms. Lindsay Rocco of Elixir Health Public Relations. You now may begin.

    Lindsay Rocco -- Investor Relations

    Thank you and good morning, everyone. We are pleased that you could join us today for Strongbridge Biopharma's fourth quarter and full year 2018 earnings conference call. Joining me from Strongbridge this morning are Matthew Pauls, President and Chief Executive Officer; Dr. Fred Cohen, Chief Medical Officer; and Brian Davis, Chief Financial Officer.

    Before we begin, I would like to remind you that during this call, the Company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the Company's periodic and current event filings with the U.S. Securities and Exchange Commission.

    In addition, this presentation includes non-GAAP financial measures. This presentation is not intended to be a substitute for financial results presented in conformity with generally accepted accounting principles in the U.S. Investors and potential investors are encouraged to review the reconciliation of the pro forma financial measures included in the Company's earnings release. The most directly comparable GAAP information and a reconciliation between the non-GAAP and GAAP figures are included in the Company's fourth quarter 2018 earnings release, which has been furnished on Form 8-K.

    I will now turn the call over to Matthew Pauls.

    Matthew Pauls -- President and Chief Executive Officer

    Thank you, Lindsay. Good morning everyone and thanks for joining us. For today's call, I'll begin by providing a brief summary of our fourth quarter and full year 2018 highlights and results. And then we'll turn the call over to Dr. Fred Cohen, our Chief Medical Officer, to discuss the ongoing Phase III clinical development program for RECORLEV. Brian Davis, our Chief Financial Officer, will then provide a financial overview. We will then open up the call for questions.

    With that, let me start by saying that Strongbridge had a strong fourth quarter from a clinical, commercial and financial perspective, which is a reflection of our momentum and overall success throughout the past year. As you will hear from the team today, our accomplishments in 2018 demonstrate the value of our rare disease strategy and have positioned us for future growth as we continue to identify, develop and commercialize important treatments for rare diseases. Leveraging the momentum from last year, we entered 2019 with a focus on progressing the development of RECORLEV for the treatment of endogenous Cushing's syndrome.

    And getting into our most notable fourth quarter accomplishments, let's start with the Novo Nordisk transactions. In December, we significantly strengthened our balance sheet with the sale of the U.S. and Canadian rights of MACRILEN to Novo Nordisk. As previously mentioned, a portion of the upfront cash payment of $145 million from Novo Nordisk to Strongbridge was used to repay all outstanding debt. Other key terms from the transaction include that Strongbridge will receive royalties on MACRILEN sales through 2027. And in addition, Novo Nordisk purchased 5.2 million ordinary shares of Strongbridge at a purchase price of $7 per share, resulting in gross proceeds of $36.7 million.

    Another important key strategic term of the transaction is that Novo Nordisk will fund Strongbridge's 23-person rare endocrine commercial field organization over the next three years to promote MACRILEN in the United States. This aligns with the Company's objective to maximize the potential of MACRILEN, while preparing for the potential regulatory approval of RECORLEV in endogenous Cushing's syndrome, a rare condition that's often treated by the same endocrinologist that diagnose and treat adult growth hormone deficiency.

    Onto our rare neuromuscular franchise. KEVEYIS, our first commercial product, enabled us to build out a rare neuromuscular franchise, which continues to be a strategic pillar for the Company. We are committed to serving the needs of the primary periodic paralysis, or PPP community, which is comprised of an estimated 4,000 to 5,000 currently diagnosed patients in the United States. As we prepare for the regulatory filing of potential launch of RECORLEV, there are many parallels and learnings that we have garnered from the KEVEYIS opportunity that we have and will continue to leverage across our business.

    Additionally, we believe that the experience and knowledge gained from launching KEVEYIS best positioned Strongbridge to acquire the rights to MACRILEN early last year, before selling the rights to Novo Nordisk at the end of the year. As part of our life cycle management planning for KEVEYIS, we are executing on a number of initiatives with the primary objective of maximizing the value of KEVEYIS over time. We believe that by the end of 2019 or into early 2020 that we will be in a position to provide an update on our life cycle management progress.

    Our investment approach with KEVEYIS focuses on three key areas. Specifically, we are focusing our KEVEYIS commercial investment on, one, utilizing sophisticated data to identify physicians that treat PPP; two, fully leveraging our CareConnection patient services model; and three, engaging the PPP community through both patient advocacy, as well as targeted social media. We look forward to executing against our 2019 plans and believe that KEVEYIS will generate a positive contribution margin by the end of the first quarter of 2020.

    So with that I'll turn the call over to Dr. Fred Cohen, our Chief Medical Officer, to discuss our clinical development progress for RECORLEV, which we believe continues to have the potential to be a first-line, first-choice therapy for patients with endogenous Cushing's syndrome.

    I will now turn the call over to Fred.

    Fredric Cohen -- Chief Medical Officer

    Thank you, Matt. Good morning, everyone. As previously announced in the third quarter, the pivotal Phase III SONICS study of RECORLEV for the treatment of endogenous Cushing's syndrome met its primary endpoint, with urinary free cortisol or UFC confirmed (ph) as normal among 30% of the intent to treat population at the end of the six-month maintenance phase.

    Detailed initial results from the SONICS study were presented in October at the European NeuroEndocrine Association Annual Meeting, with additional data presented at the European Network for the study of Adrenal Tumors Annual Meeting in November. These analyses illustrated the favorable effects of RECORLEV on hypercortisolism and its comorbidities, particularly sustained improvements in markers of cardiovascular risk, such as LDL-cholesterol, hemoglobin A1C and body weight.

    Further SONICS results from the end of maintenance analyses are planned for presentation at the International Pituitary Congress and the Endocrine Society's Annual Meetings in late March, and at the American Association of Clinical Endocrinology Meeting in April. These results will highlight additional benefits of RECORLEV on the signs and symptoms of hypercortisolism.

    Additionally, submission of a manuscript of the primary efficacy and safety data from SONICS to a peer-reviewed journal is anticipated in the first half of 2019. One-year data from the completed SONICS study are expected to be available in the first half of 2019. These data will include findings from the six-month extended evaluation phase, which is primarily intended to characterize the long-term safety, tolerability and benefit-risk profile of RECORLEV.

    From a regulatory standpoint, a Type C meeting with the FDA is planned within this quarter to seek guidance on the path forward to obtain marketing approval for RECORLEV in the United States, and that process is on track. We anticipate providing an update in the second quarter.

    Finally, the receipt of top line results from the Phase III LOGICS study remains on track for the fourth quarter of 2019. As a reminder, LOGICS is a double blind trial with no planned interim analyses prior to the receipt of these anticipated results.

    And with that, I will now turn the call over to Brian Davis for a financial overview.

    A. Brian Davis -- Chief Financial Officer

    Thank you, Fred. Our press release contain details of our financial results for the fourth quarter and full year 2018. Rather than read all of those details, my comments will center on a few highlights.

    As noted in the press release, our guidance for KEVEYIS revenues in 2019 is in the $18 million to $20 million range. We have significantly improved our financial and strategic flexibility as a result of the cash proceeds and anticipated future payments from our transactions with Novo Nordisk, as well as the repayment in full of our outstanding debt. We ended 2018 with $122.5 million of cash, cash equivalents and no outstanding debt. As for cash runway, we believe the combination of our existing cash resources, anticipated KEVEYIS revenues and payments from Novo Nordisk, as well as the continued prudent management of our operating expenses will provide sufficient capital to support our operations, at least through the first quarter of 2021.

    And Catherine, with that, we are now ready to open up the call for questions.

    Questions and Answers:


    (Operator Instructions) And our first question comes from Esther Hong with Janney. Your line is open.

    Esther Hong -- Janney -- Analyst

    Hi, good morning. Thanks for taking my questions. So with respect to the Type C FDA meeting over RECORLEV, can you provide additional details on your expectations, and then, any potential logistics regarding accelerator approval? And then the second question is, any updates on business development plans in 2019? Thanks.

    Matthew Pauls -- President and Chief Executive Officer

    So Esther, this is Matt. Thank you for the questions. Let me take them in reverse order. With regard to business development, we obviously don't comment on any business development-related projects that we may be working on. I do think that our history here at Strongbridge -- as we continue to build the Company is that we are active in looking at opportunities and that continues. And that's all I'll say on that front. I will have Dr. Cohen comment on the Type C regulatory process and timing.

    Fredric Cohen -- Chief Medical Officer

    Sure. So as I've just -- we do plan to have the discussion with the FDA in the first quarter of this year, and then following digestion of that and then any clarifying dialog we need to have with the FDA, we plan to update investors by the second quarter with the path forward, as we said. In terms of our base case, just to reiterate, we are anticipating that the FDA will guide us toward the need for both the full SONICS as well as the full LOGICS study for being in hand and included within NDA. Again, that's the base case. The upside case for us that we believe is supported with the unmet medical need, the way that SONICS was designed in terms of using a surrogate endpoint that's been established, and the precedent within this division of allowing approval on the basis of the single open label study, we believe that there is an upside case where there could be an accelerated pathway toward the filing, where we base it primarily just on the SONICS, to your point around accelerator approval. Again, we do think that the dialog that we're anticipating with the FDA in this quarter will make that pathway clear for us and then we'll update you guys accordingly.

    And with regard to timing, that's just so -- in the expedited or accelerated upside case, clearly we would be working hard to get it -- get the NDA filed as quickly as possible, probably realistically why we would love to have it filed by the end of the year, at the end of 2019, it probably would be more like an early 2020-ish. More details to come on that, obviously, as we have more clarity. In the base case, it would be about a year later than that. I hope that helps.

    Esther Hong -- Janney -- Analyst

    It does. Great, thank you.

    Fredric Cohen -- Chief Medical Officer

    You are welcome.


    Thank you. And our next question comes from Annabel Samimy with Stifel. Your line is open.

    Nick Rubino -- Stifel -- Analyst

    Good morning, everyone. This is Nick Rubino on for Annabel Samimy. Thanks for taking our question. First, how the efforts to educate physicians on titration helped patient retention. Are you still seeing attrition due to the side effects and how do you see those dynamics playing out 2019 and beyond? And then second with the one-year SONICS, you had mentioned the safety pieces, but are we getting efficacy measures as well? And then, if I can just sneak in a quick fast one, with the MACRILEN revenue numbers you reported this quarter, are those purely royalty revenues or did those include full sales from October and November? Thanks.

    Matthew Pauls -- President and Chief Executive Officer

    Thanks for those questions, Nick. Let me give you a little insight on the first question regarding KEVEYIS. We learned a lot on the KEVEYIS fronts in 2018 regarding both KEVEYIS as well as primary periodic paralysis. And one of the key learnings which you well said was around the need, often to go a little bit lower and a little bit slower in the titration period. And, I'll ask Dr. Cohen just to comment briefly on that. I think, we have some learnings from Phase III trial and then from the clinical -- not just clinical instant -- in the clinical trial, but also in the commercial use too. So, Fred, do you want to comment on that?

    Fredric Cohen -- Chief Medical Officer

    Yeah. Yeah, sure. Great. So one of the things that we learned was that there are a significant minority of patients who experienced adverse reactions from the drug early on in the therapy. And one of them -- one of those reactions that's common is on -- a confusion on mental fog, if you will, that occurs. It's a transient response to the drug until the brain can sort of equilibrate and become used to the drug. But when it occurs, it needs to be addressed, it needs to be managed, and the best way that we know how to manage it is by lowering the dose of the drug.

    Well, it took us a while, I think, number one, to recognize that this was a reaction that was responsible for some patients discontinuing from the drug. And once we did recognize that, we put in place a series of educational efforts aimed at physicians initially and then later direct-to-patient education and care through the use of, for example, patient ambassadors that have given their time generously to help educate other patients. And so we're making great progress. I think, it's fair to say we've seen already changes in the way the titrations are going. And we've gotten feedback from patients who are now able to overcome the initial side-effects and have stayed on the drug, because they are seeing benefits from it in many cases. So, I hope that addresses that part of that question.

    Nick Rubino -- Stifel -- Analyst

    Yes, that's great. Then, with regards to the --

    Matthew Pauls -- President and Chief Executive Officer

    Yes, the MACRILEN revenues during the fourth quarter were product sales by Strongbridge. There were no royalties in our revenues for the quarter.

    Fredric Cohen -- Chief Medical Officer

    Yes, there was also a question you had about the 1-year RECORLEV data. So on the top line data that we will be sharing with you will include primarily safety data. But also we did measure some efficacy data as well, including urine free cortisol, as well as those comorbidity markers. And I'm pretty sure we'll be sharing that with you at the time we release the top line results.

    Nick Rubino -- Stifel -- Analyst

    Alright. Great. Thank you guys.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, thanks for the questions.


    Thank you. And our next question comes from Hartaj Singh with Oppenheimer & Company. Your line is open.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great, thanks. Thanks for the question and a good year. Just a couple of questions, Matt I've got. On your interactions with the FDA prior to this meeting, I assume you might have already submitted a sort of a briefing package and kind of there have been some interactions back and forth. Can you just give some color on, sort of, the gist of those interactions and what are some of the questions that maybe you're asking or FDA is wanting to be addressed prior to the actual meeting? And then a second question, just on KEVEYIS, to follow up with the previous question. Matt, can you just give some color on, sort of, new patients, continuing patients, what sort of -- how many patients are staying on drug, on average, just any color around what that dynamic is, because it seems that the drug is growing quarter-on-quarter. And then just your thoughts about that going forward. And then just a quick housekeeping question after that. Thank you.

    Matthew Pauls -- President and Chief Executive Officer

    Great, thank you Hartaj. So on the regulatory question related to RECORLEV. As a standard course for us, we don't comment on the interactions prior to having our final interpretation of the dialog. So more to come in the second quarter. And I think, Fred articulated well earlier what our base case assumptions are meeting both trials and the upside case around an accelerated potential approval, given the significant unmet need in Cushing syndrome, UFC being a stated accepted surrogate endpoint by the FDA, resoundingly positive, and we think compelling SONICS data. And then, in this division, in the review of Cushing's syndrome, single trial approvals. So that's where we're at and we'll provide an update in the second quarter.

    And then with regard to KEVEYIS -- and your question on KEVEYIS. So what we know is that there -- we are confident there are 4,000 to 5,000 patients currently diagnosed with PPP. We are seeing new patients regularly come onto KEVEYIS. And we are doing a much better job, as Fred mentioned, with regard to patient-to-patient interaction, patient-to-physician interaction, recommendations around maybe lower and slower titration or down titration. So we are seeing patients more often than not -- now stay on the drug through that kind of an interim period.

    And so, the big focus for us here is being smart and choiceful about our investment level with regard to KEVEYIS, because it's important for many reasons to try to drive KEVEYIS to profitability on a stand-alone basis as quickly as possible. And we're confident that we're on that path by the end of the first quarter of 2020. And parallel to that, given the fact that there are no other drugs really that are in development for the treatment of this ultra-rare genetic neuromuscular condition, PPP, we are working very feverishly and hard, as we've said previously, around life cycle management opportunities. We would love to have the opportunity to have more runway with KEVEYIS. So more to come by the -- probably by the end of the year, again, maybe into 2020 on our life cycle management plans. But this is a market that prior to us relaunching the drug really had no investment ever, was disorganized, unstructured. And we're confident that we're on the path to structuring it, organizing it and getting KEVEYIS to profitability, so that we're being smart and choiceful and wise with regard to our investment.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great. And Matt, that's great color. Just a follow-up on that. So roughly speaking, are you sort of seeing patients that are coming that are new to KEVEYIS being equal to patients dropping off, or is there less of a drop-off, just what's the dynamic there between the new and the continuing patients and the patients that are leaving, whether it's titration or for other issues?

    Matthew Pauls -- President and Chief Executive Officer

    So, we -- the trend is that more patients are staying on the drug than off. And that's based on the interventions, really in -- I guess in the back half of the third quarter and the fourth quarter by us, and of course to-date. So what we're -- the patient identification and identifying patients who are very motivated and physicians that are motivated and then providing the very strong level of support and service for them through that process, given the potency of KEVEYIS. I mean the drug really works. It really works. We are having success getting patients through that short -- I don't know -- for a four-to-six-week period-ish, that range. But it's upwards of eight weeks.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Got it. And then just one housekeeping question on -- just how to think about operating expenditures, sort of, going forward for the year, just any thoughts there? And again, thank you so very much.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, Hartaj. This is Brian, Hartaj. Thanks for that. So, on the cash basis, as I mentioned, we're looking at a runway that takes us through the first quarter of 2021. I think we have the benefit of the Novo Nordisk subsidy coming online here in 2019 to offset the commercial effort around MACRILEN. And so we'll have a little transition working through Q1 to get down on a cash burn basis. But we feel pretty comfortable in that low-to-mid teens area as we move forward. In fact, if you take that $122 million cash balance and just by simple averaging over the subsequent nine quarters through the first quarter of 2021 that comes up to about $13.5 million. So a little more in this year, reflecting the transition down, reflecting we've got some increased RECORLEV program expenses (inaudible) high water mark, if you will, for the RECORLEV program, because we have SONICS and LOGICS and OPTICS running simultaneously, but obviously SONICS expense is winding down now that the one-year data will be coming through. So again, enough cash to get us at least through the first quarter. And obviously, we'll have more definition on that as we go along as to how much more at least it can be.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great. And I really appreciate it. Thank you very much.


    Thank you. And our next question comes from Liisa Bayko with JMP Securities. Your line is open.

    Liisa Bayko -- JMP Securities -- Analyst

    Hi, congratulations on the quarter. Just a couple of questions for me, mainly about KEVEYIS. So first of all, I want to say congratulations, I mean you've made this into a product that reached $20 million this year, which is certainly a lot higher than where you thought the product couple of years ago. We technically were only talking about $1 million. So it's obvious that you've done a tremendous job in creating this market. But again (ph) your guidance a little bit, for this year, looks like $4.4 million is the kind of what you're coming off 4Q (ph). Your guidance of $18 million to $20 million implies a little bit of slowing growth. So is that -- are patients adds still happening at the same rate or is that lower, are you having -- struggling to find more patients or is it based on -- basically from your comments, I'm thinking maybe less revenue per patient because of dose titration. What's the kind of dynamic with add indications or revenue per patient? How does that -- what's sort of underlying the guidance?

    A. Brian Davis -- Chief Financial Officer

    Yes, this is Brian. So again, we're continuing the good news, is find patients. And we feel really good about the field force we have in place and they're performing very strongly, as Matt indicated in his comments and in the prior answer. We've had a lot of learning in this market and working through how best not only to attract patients, but also to retain patients. So we were conscious of the revenue range that we put out there, $18 million to $20 million and where we've come off of this year, we're going to be conservative in our approach, But the patient retention piece takes time and we think we're working through it.

    On the expense side, we have focused our investment and made decisions to decrease the territories to help make sure we get to a positive contribution margin or a profitability standpoint for the product. We went from 21 down to 17 territories. We focused our marketing expenses to those -- really targeted toward the patient, in order to help all of the revenue expenses to line up. So, we'll keep working through it, but we feel good about our ability to not only hit this range, but also to get this product to be one that's a profitable one. And as you pointed out at the beginning, it was a very challenging market to enter into. You're quite correct. Before we had acquired the drugs -- the drug, I should say, its sales had been less than $1 million in a year. So, yes.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, so Liisa, the other piece on that to note is, as I mentioned, in parallel, we are looking at life cycle management opportunities and we'll update the market probably by the end of the year or in early 2020. And if there are potential opportunities to extend the life and runway of KEVEYIS, we will obviously, probably revisit our investment strategy with regard to the brand. But right now, it is to get it to profitability as quickly as possible and to grow the top line, which we will do both. And exiting the year, the low end of the range, we're tracking already to the low end of the range. So hopefully, there will be some -- even more enhanced or increased momentum as we go the year.

    Liisa Bayko -- JMP Securities -- Analyst

    Okay, fair enough. And then, I guess, as you look longer-term, are you still thinking this product is kind of easily a couple hundred million or do you have some other kind of target in mind longer-term now that you've had more experience selling the drug? Just thinking about how, kind of, directionally where we should be headed in terms of modeling. Thanks.

    A. Brian Davis -- Chief Financial Officer

    I think -- this is Brian. I think, there's a couple of things there, Liisa, that really play into that. So one is the patient penetration. So we think we've got an opportunity and we're really just at the beginning stages of it in terms of patient penetration. Now Matt and Fred were taking a little bit earlier about life cycle management opportunities, having a longer commercial runway will certainly allow us the opportunity to reach peak sales levels over a longer period of time that we have (inaudible). We're just operating with the current regulatory exclusivity. I think, the other piece that obviously plays into in this environment is around the price of the drug. And I would note, we continue to be very cautious in our thinking around that. So we'll talk about pricing strategy, specifically, but we're very aware of the environment that we're in and we're going to act appropriately in that environment, and really try to do all we can to make sure patients -- as many patients have access to the drug as possible over time. But we think there's a longer runway in terms of reaching out to patients and life cycle management opportunities would certainly help to get us up to higher peak sales levels.

    Liisa Bayko -- JMP Securities -- Analyst

    Okay. Thank you very much for your comments. Appreciate it.

    A. Brian Davis -- Chief Financial Officer

    Thanks Liisa.


    Thank you. And I'm showing no further questions at this time. I'd like to turn the call back to Mr. Matthew Pauls for any closing remarks.

    Matthew Pauls -- President and Chief Executive Officer

    Thank you. In summary, these fourth quarter and full year 2018 results underscore that our strategy, our assets, our people, our capital and our infrastructure well position us for continued success in 2019 and beyond. Thank you for joining today's call and for your continued support.


    Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may all disconnect. Everyone have a great day.

    Duration: 33 minutes

    Call participants:

    Lindsay Rocco -- Investor Relations

    Matthew Pauls -- President and Chief Executive Officer

    Fredric Cohen -- Chief Medical Officer

    A. Brian Davis -- Chief Financial Officer

    Esther Hong -- Janney -- Analyst

    Nick Rubino -- Stifel -- Analyst

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Liisa Bayko -- JMP Securities -- Analyst

    More SBBP analysis

    Transcript powered by AlphaStreet

    This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

    Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

    Nektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium | killexams.com real questions and Pass4sure dumps

    SAN FRANCISCO, Feb. 25, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, Dr. Adi Diab, and company management on Friday, March 1, 2019 at 3:00 p.m. Pacific Time during the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The event will follow Friday's oral presentation by Dr. Diab of preliminary data from the ongoing dose-escalation stage of the REVEAL Phase 1/2 clinical study evaluating the combination of TLR agonist, NKTR-262, with a CD122-preferential IL-2 pathway agonist, bempegaldesleukin* (NKTR-214), in patients with locally advanced or metastatic solid tumors.

    Details on the Analyst Call:

    Date and Time: Friday, March 1, 2019 at 3:00 p.m. Pacific Time

    Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (international)

    Passcode: 6970019

    The conference call will include lead investigator on the REVEAL study, Dr. Adi Diab, Assistant Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center. The webcast and slides for the conference call can be accessed through a link that is posted on the Investors section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. The event will also be available for replay for two weeks on the company's website, www.nektar.com.

    Details on the Oral Presentation at ASCO-SITC:

    Abstract Title: "Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 

    agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid

    tumors (REVEAL Phase Ib/II Trial)"

    Abstract: #28

    Presenter: Dr. Adi Diab, MD Anderson Cancer Center

    Session: Oral Abstract Session B

    Date and Time: Friday, March 1, 2019, 1:00 p.m.-2:15 p.m. Pacific Time

    About NektarNektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at www.nektar.com.

    * rINN (recommended International Nonproprietary Name)


    View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-to-webcast-conference-call-for-analysts-and-investors-at-the-2019-asco-sitc-clinical-immuno-oncology-symposium-300801596.html

    American Outdoor Brands Corporation® Third Quarter Fiscal 2019 Financial Release and Conference Call Alert | killexams.com real questions and Pass4sure dumps

    SPRINGFIELD, Mass., Feb. 22, 2019 /PRNewswire/ -- American Outdoor Brands Corporation (nasdaq global select:AOBC) today announced that it plans to release its third quarter fiscal 2019 financial results on Thursday, March 7, 2019, after the close of the market. The full text of the press release will be available on the American Outdoor Brands web site at www.aob.com under the Investor Relations section.

    The company will host a conference call and webcast on March 7, 2019, to discuss its third quarter fiscal 2019 financial and operational results. Speakers on the conference call will include James Debney, President and Chief Executive Officer, and Jeffrey D. Buchanan, Executive Vice President and Chief Financial Officer. The conference call may include forward-looking statements. The conference call and webcast will begin at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Those interested in listening to the conference call via telephone may call directly at (844) 309-6568 and reference conference identification number 9683518. No RSVP is necessary. The conference call audio webcast can also be accessed live and for replay on the company's website at www.aob.com, under the Investor Relations section. The company will maintain an audio replay of this conference call on its website for a period of time after the call. No other audio replay will be available.

    About American Outdoor Brands Corporation American Outdoor Brands Corporation (nasdaq global select:AOBC) is a provider of quality products for shooting, hunting, and rugged outdoor enthusiasts in the global consumer and professional markets. The Company reports two segments: Firearms and Outdoor Products & Accessories. Firearms manufactures handgun long gun, and suppressor products sold under the Smith & Wesson®, M&P®, Thompson/Center Arms™, and Gemtech® brands, as well as provides forging, machining, and precision plastic injection molding services. AOB Outdoor Products & Accessories is the industry leading provider of shooting, reloading, gunsmithing, gun cleaning supplies, specialty tools and cutlery, and electro-optics products and technology for firearms. We produce innovative, top quality products under the brands Caldwell®; Wheeler®; Tipton®; Frankford Arsenal®; Lockdown®; BOG®; Hooyman®; Smith & Wesson® Accessories; M&P® Accessories; Thompson/Center Arms™ Accessories; Schrade®; Old Timer®; Uncle Henry®; Imperial®; BUBBA®; UST®;  Lasergrips®, Laserguard®, LiNQ®, Lightguard®, Defender Series™, Rail Master®, and LaserLyte.  For more information on American Outdoor Brands Corporation, call (844) 363-5386 or log on to www.aob.com.  

    Contacts:Liz Sharp, VP Investor RelationsAmerican Outdoor Brands Corporation(413) 747-6284lsharp@aob.com

    View original content to download multimedia:http://www.prnewswire.com/news-releases/american-outdoor-brands-corporation-third-quarter-fiscal-2019-financial-release-and-conference-call-alert-300800591.html

    SOURCE American Outdoor Brands Corporation

    Copyright (C) 2019 PR Newswire. All rights reserved

    Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [48 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [13 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [750 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1532 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [64 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [374 Certification Exam(s) ]
    Mile2 [3 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [39 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [279 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [12 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]

    References :

    Dropmark : http://killexams.dropmark.com/367904/11788593
    Wordpress : http://wp.me/p7SJ6L-1FZ
    Dropmark-Text : http://killexams.dropmark.com/367904/12550696
    Blogspot : http://killexamsbraindump.blogspot.com/2017/12/free-pass4sure-920-106-question-bank.html
    RSS Feed : http://feeds.feedburner.com/EnsureYourSuccessWithThis920-106QuestionBank
    Box.net : https://app.box.com/s/v3e63p1mihwq6ygnznh96frr77zwlpp6

    View Practice Questions »

    We Make Sure Q&A work for you!

    See Entry Test Preparation   |   Project Management, English Tests Home

    Pass4sure PDFs (Pass4sure Questions and Answers), Viewable at all devices like PC Windows (all versions), Linux (All versions), Mac / iOS (iPhone/iPad and all other devices), Android (All versions). It support High Quality Printable book format. You can print and carry anywhere with you, as you like.

    Testing and Training Engine Software (Pass4sure Exam Simulator) Compatible with All Windows PC (Windows 10/9/8/7/Vista/XP/2000/98 etc). Mac (Through Wine, Virtual Windows PC, Dual boot). It prepares your test for all the topics of exam, gives you exam tips and tricks by asking tricky questions, uses latest practice quiz to train you for the real test taking experience in learning mode as well as real test mode. Provides performance graphs and training history etc.

    Read more »

    More Useful Links about 920-106

    Certification Vendors Here   |   View Exams, Latest Home

    Information Links


    Killexams Exam Study Notes | study guides - list.php
    Pass4sure [EC] Certification Exam Questions and Answers - pass4sure-cert.php
    Pass4sure [EC] Training Questions and Answers - pass4sure-cert.php
    Killexams Exam Study Notes | study guides - approids.co.uk
    Certification Questions and Answers | Exam Simulator | Study Guides - killexams-exam-list.php
    Pass you exam at first attempt with Pass4sure Questions and Answers - c4m.php
    Pass4sure [EC] Certification Exam Questions and Answers - pass4sure-cert.php
    Pass4sure Real Questions and accurate answers for exam - pass4sure-list.php
    Pass you exam at first attempt with Pass4sure Questions and Answers - list.html
    [EC] Real exam Questions and Answers with Exam Simulators - pass4sure-cert.php

    View Practice Questions »

    Services Overview

    We provide Pass4sure Questions and Answers and exam simulators for the candidates to prepare their exam and pass at first attempt.

    Contact Us

    As a team are working hard to provide the candidates best study material with proper guideline to face the real exam.

    Address: 15th floor, 7# building 16 Xi Si Huan.
    Telephone: +86 10 88227272
    FAX: +86 10 68179899
    Others: +301 - 0125 - 01258